Actively Recruiting
Study of Tumor Cell Changes After Y90 Transarterial Radioembolization for Liver Metastases from Colorectal Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-03-12
80
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying how radioembolization affects tumor cells in people with colorectal cancer that has spread to the liver. This research aims to improve the radioembolization procedure and understand how tumors respond to the treatment. The study focuses on patients with liver metastases deemed suitable for Y90 transarterial radioembolization TARE. Participants will receive Y90 TARE as part of their standard clinical care, either targeting large liver areas or smaller segments depending on tumor spread. After the procedure, participants will undergo PETCT or PETMRI scans to measure radiation doses delivered to tumors and healthy liver tissue. The study includes biopsy sampling of tumors after treatment to assess radiation effects. During the study, researchers will collect biopsy samples and perform scans to evaluate tissue damage and radiation-induced injury at two time points 72 hours and between 14 to 21 days after treatment. This helps correlate radiation doses with tumor and liver tissue response. Participants health status and blood tests will be monitored to ensure safety throughout the study period.
CONDITIONS
Brief Title
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
Research Team
C
Constantinos T Sofocleous, MD, PhD
A
Assen Kirov, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
